Stavanger University Hospital, Stavanger, Norway.
Eur J Heart Fail. 2012 Jan;14(1):61-73. doi: 10.1093/eurjhf/hfr158.
The European CRT Survey is a joint initiative of the Heart Failure Association (HFA) and the European Heart Rhythm Association (EHRA) of the European Society of Cardiology evaluating the contemporary implantation practice of cardiac resynchronization therapy (CRT) in Europe.
Patients who had a successful CRT implantation were enrolled from 141 centres in 13 countries between November 2008 and June 2009. Baseline demographics, clinical and implantation data were collected, with a follow-up of ∼1 year (9-15 months). The current report describes clinical outcomes including symptom severity, cardiovascular (CV) hospitalization, and survival. A total of 2438 patients were enrolled, and follow-up data were acquired from 2111 patients (87%). The population included important groups of patients poorly represented in randomized controlled trials, including very elderly patients and those with prior device implantation, atrial fibrillation, and/or QRS duration <120 ms. Investigators reported substantial improvement in New York Heart Association (NYHA) functional class at follow-up. Patient self-assessment indicated that 81% of the patients felt improved, 16% reported no change, and 4% reported deterioration. During follow-up, 207 (10%) patients died, 346 (16%) had a CV hospitalization, and 501 (24%) died or had CV hospitalization. Worse NYHA functional class, atrial fibrillation, ischaemic aetiology, and device type (CRT-P, i.e. CRT alone) were associated with poorer survival. Women had a better outcome, as did patients who had a CRT-D (with an implantable cardioverter defibrillator function) device.
Outcomes including death and hospitalization in this European CRT survey were consistent with results from clinical trials of CRT. At 1 year follow-up, most patients who received a CRT device considered their symptoms improved compared with their pre-implant assessment. Although prospective, this is an observational study of successful CRT implantations, and outcomes in subgroup analyses must be interpreted with appropriate conservatism.
欧洲 CRT 调查是心力衰竭协会(HFA)和欧洲心脏病学会的欧洲心律协会(EHRA)的联合倡议,旨在评估欧洲心脏再同步治疗(CRT)的当代植入实践。
2008 年 11 月至 2009 年 6 月期间,从 13 个国家的 141 个中心招募了成功接受 CRT 植入的患者。收集了基线人口统计学、临床和植入数据,并进行了约 1 年(9-15 个月)的随访。本报告描述了临床结局,包括症状严重程度、心血管(CV)住院和生存率。共纳入 2438 例患者,其中 2111 例(87%)患者获得了随访数据。该人群包括在随机对照试验中代表性较差的重要患者群体,包括非常高龄患者和那些有先前设备植入、房颤和/或 QRS 持续时间<120ms 的患者。研究人员报告称,在随访时纽约心脏协会(NYHA)功能分级有显著改善。患者自我评估表明,81%的患者感觉改善,16%的患者报告无变化,4%的患者报告恶化。随访期间,207 例(10%)患者死亡,346 例(16%)发生心血管住院,501 例(24%)死亡或心血管住院。较差的 NYHA 功能分级、房颤、缺血性病因和设备类型(CRT-P,即 CRT 单独)与较差的生存率相关。女性的结局更好,CRT-D(具有植入式心脏复律除颤器功能)患者的结局也更好。
本欧洲 CRT 调查的结局,包括死亡和住院,与 CRT 的临床试验结果一致。在 1 年随访时,大多数接受 CRT 设备的患者认为与植入前评估相比,他们的症状有所改善。尽管这是一项前瞻性研究,但这是一项成功 CRT 植入的观察性研究,亚组分析的结果必须谨慎解释。